Back

Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Optimal risk factor therapy in high risk patients Drug therapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Ms Britt Heidemann

University Medical Center Utrecht, Utrecht (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial
Doctor A. Sharma (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking
Professor M. Miller (Philadelphia, US)
Abstract Slides Video
Presentation thumbnail
Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia
Doctor A. Wiegman (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
The effect of achieving LDL-C <1.8 mmol/L to prevent the first atherosclerotic cardiovascular events in the primary prevention settings of severe heterozygous familial hypercholesterolemia
Doctor S. Funabashi (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Clinical consequences of the lipid-lowering treatment in patients with acute coronary syndrome: real-world retrospective study (LipidACS study)
Doctor J. Alarcon (Donostia, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Optimal risk factor therapy in high risk patients

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Breaking through: CETP inhibitors and the future of lipid therapy
thumbnail
Congress Presentation
What’s new on lipid-lowering drugs: from statins to gene editing and beyond
thumbnail
Congress Presentation
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources